Lidocard

Lidocaine Hydrochloride, the active ingredient in Lidocard, is a local anesthetic presented as an injection solution for intravenous use. It provides reversible loss of sensation for procedures requiring local anesthesia and is employed in the acute management of ventricular arrhythmias in appropriate patients.

GNH USA supplies Lidocard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocard is a local anesthetic and anti‑arrhythmic agent used in specific clinical pathways. - Local anesthesia: provides reversible loss of sensation for minor surgical, dental or diagnostic procedures. - Ventricular arrhythmias: stabilises cardiac rhythm during acute ventricular tachycardia or fibrillation. - Peripheral nerve block: facilitates regional anaesthesia for limb surgeries.

Lidocard may cause a range of adverse reactions, most of which are dose‑related.

Common Side Effects: - Dizziness or light‑headedness - Metallic taste in the mouth - Numbness or tingling at the injection site - Mild hypotension or flushing

Serious or Rare Side Effects: - Seizures - Severe allergic reaction (anaphylaxis) - Cardiac arrest or profound arrhythmia

When using Lidocard, clinicians should observe several safety measures. - Dose adjustment: reduce dosage in patients with hepatic impairment. - Cardiac monitoring: continuous ECG is required during intravenous administration. - Avoid rapid bolus: inject slowly to minimise central nervous system toxicity. - Contraindications: known hypersensitivity to amide‑type local anesthetics. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lidocard can interact with several drug classes; awareness of the interaction level is essential.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine) – may increase lidocaine plasma concentrations. - CYP3A4 inhibitors (e.g., ketoconazole) – can raise systemic exposure. - Beta‑blockers – may enhance cardiac depressant effects.

Moderate Interactions (Monitor Closely): - Diuretics – may alter electrolyte balance affecting cardiac response. - Other local anesthetics – cumulative toxicity risk when combined.